The Piper Jaffray Cos. Analysts Give Alnylam Pharmaceuticals Inc. (ALNY) a $106.00 Price Target

The Piper Jaffray Cos. Analysts Give Alnylam Pharmaceuticals Inc. (ALNY) a $106.00 Price Target

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has been given a $106.00 price target by research analysts at Piper Jaffray Cos. in a report released on Thursday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target would suggest a potential upside of 192.74% from the stock’s previous close.

Other analysts have also issued reports about the company. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Leerink Swann reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Cowen and Company reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Needham & Company LLC reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, June 13th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, June 10th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $86.00.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 7.84% during mid-day trading on Thursday, hitting $33.37. The company had a trading volume of 4,245,952 shares. The stock’s market cap is $2.86 billion. Alnylam Pharmaceuticals has a 52-week low of $33.28 and a 52-week high of $110.75. The stock’s 50-day moving average is $71.80 and its 200-day moving average is $66.24.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same period last year, the company posted ($0.85) earnings per share. The firm’s revenue was up .2% compared to the same quarter last year. Equities analysts forecast that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current year.

In other news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the transaction, the chief executive officer now directly owns 148,465 shares in the company, valued at $9,604,200.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.00% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $128,000. Seven Eight Capital LLC increased its position in shares of Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 1,800 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $175,000. Bank of Montreal Can acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $193,000. Finally, BlueMountain Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

About Alnylam Pharmaceuticals

Related posts

Leave a Comment